Innovative Method of Alopecia Treatment Using Adipose-Derived Stromal Vascular Fraction Cells

June 2021 in “ Research Square (Research Square) ”

Kim Sj, Mi‐Hyun Kim, Lee Y, Lee J, Jae‐Hun Kim, Do-Hyung Kim, Do Yh, Choi Jw, Chung Si, Do Br

adipose-derived stromal vascular fraction cells SVF cells androgenetic alopecia AGA autologous SVF hair density keratin SVF hair loss hair thickness

Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

Studysummary This study reports that a single injection of stromal vascular fraction (SVF) cells into the scalp of patients with androgenetic alopecia significantly increased hair density and thickness within 3 to 6 months, with no observed side effects.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on researchsquare.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

A Randomized, Double-Blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia

research A Randomized, Double-Blind, Vehicle-Controlled Clinical Study of Hair Regeneration Using Adipose-Derived Stem Cell Constituent Extract in Androgenetic Alopecia

25 citations , May 2020 in “Stem Cells Translational Medicine”

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

research Stromal Vascular Fraction-Enriched Platelet-Rich Plasma Therapy Reverses the Effects of Androgenetic Alopecia

20 citations , September 2019 in “Journal of Cosmetic Dermatology”

This study found that combining stromal vascular fraction with PRP injections significantly improved hair density and reduced hair loss more effectively than PRP alone in patients with androgenetic alopecia.

research Keratin-Based Particles for Protection and Restoration of Hair Properties

17 citations , July 2018 in “International Journal of Cosmetic Science”

This study found that keratin-based particles were able to recover and enhance the mechanical properties and thermal stability of virgin and overbleached Asian hair, improving its strength and smoothness by around 40%, and demonstrated safety in human skin keratinocytes.

Introducing Platelet-Rich Stroma: Platelet-Rich Plasma and Stromal Vascular Fraction Combined for the Treatment of Androgenetic Alopecia

research Introducing Platelet-Rich Stroma: Platelet-Rich Plasma and Stromal Vascular Fraction Combined for the Treatment of Androgenetic Alopecia

40 citations , March 2018 in “Aesthetic Surgery Journal”

This study found that a single injection of platelet-rich stroma significantly increased hair density in men with androgenetic alopecia within 6 to 12 weeks, with no reported side effects.

Up-To-Date Clinical Trials of Hair Regeneration Using Conditioned Media of Adipose-Derived Stem Cells in Male and Female Pattern Hair Loss

research Up-To-Date Clinical Trials of Hair Regeneration Using Conditioned Media of Adipose-Derived Stem Cells in Male and Female Pattern Hair Loss

30 citations , June 2017 in “Current stem cell research & therapy”

This review discusses the potential of adipose-derived stem cells for hair regeneration and suggests that these cells and their conditioned media may offer a promising strategy for treating hair loss.

research Stem Cell Therapy as a Novel Therapeutic Intervention for Resistant Cases of Alopecia Areata and Androgenetic Alopecia

39 citations , August 2016 in “Journal of Dermatological Treatment”

This study observed that autologous bone marrow derived mononuclear cells and follicular stem cells were both safe and effective for improving resistant alopecia areata and androgenetic alopecia, with no serious adverse events.

research Androgenetic Alopecia: An Update Of Treatment Options

110 citations , August 2016 in “Drugs”

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men

198 citations , October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft”

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.

research Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men

112 citations , October 2005 in “Mayo Clinic Proceedings”

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

research A Randomized, Placebo-Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss

219 citations , March 2004 in “Journal of The American Academy of Dermatology”

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

research A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men

269 citations , August 2002 in “Journal of The American Academy of Dermatology”

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.